Cure8 research brief
The study describes a new oral-delivery microsphere that improved loading and gut-targeted release of celastrol and showed beneficial effects in a mouse colitis model and on gut microbiota. If translatable, this approach could help deliver poorly soluble anti-inflammatory drugs to the inflamed intestine.
Preclinical researchers, formulation scientists, IBD translational researchers, and clinicians following experimental therapeutics.
This study describes a laboratory and animal-model evaluation of a new oral microsphere formulation (chitosan-coated, sodium-phytate–crosslinked porous starch) designed to deliver celastrol to the inflamed gut.
The abstract reports improved drug loading, reduced premature release, protective effects on inflamed macrophages in vitro, restoration of colon length and spleen index, reduced macrophage infiltration, recovery of tight-junction proteins, and shifts in gut microbiota in a DSS mouse colitis model.
The work is preclinical: evidence comes from formulation characterization, cell experiments, 16S rRNA microbiome sequencing, and a dextran sulfate sodium (DSS)–induced murine colitis model rather than human trials.
The results suggest the platform may improve oral delivery of poorly soluble anti-inflammatory compounds and indirectly modulate microbiota by reducing inflammation. If you are a patient, caregiver, or clinician, note this is an early-stage, nonclinical study.
It does not provide evidence about safety or effectiveness of this formulation or celastrol in people with IBD.
Findings come from in vitro and DSS mouse-model experiments reported in the article abstract; human safety and efficacy are not addressed.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could bias the work reported in this paper.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Researchers are exploring methods to make probiotic therapies more stable through the digestive tract and to deliver anti-inflammatory molecules directly where intestinal inflammation produces high reactive oxygen...
Researchers are exploring microbiome-derived molecules as targeted, locally acting therapies for ulcerative colitis that might avoid systemic immunosuppression. EB1010 showed anti-inflammatory activity and...
Fibrosis and stricturing are key problems in Crohn’s disease with limited therapies; this study identifies a microbiota–bile acid–GPBAR1 pathway by which a specific probiotic mix reduced inflammation and fibrosis in...
